Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...
Q4 2024 Earnings Call Transcript November 12, 2024 Operator: Greetings and welcome to the Azenta Fourth Quarter 2024 ...
We do not require IP-administered LMPs or complex delivery vehicles ... myeloblasts that give rise to new myocytes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback